Form 4: Castle Bio COO Converts PSUs, Sells for Tax

Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, converted performance-based stock units into common stock and subsequently sold shares to cover tax obligations.

Summary

• Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc. (CSTL), converted 10,640 performance-based stock units (PSUs) into common stock on August 8, 2025.
• These PSUs represented the remaining 50% of a grant issued on December 23, 2022, and fully vested on August 9, 2024.
• Following the conversion, 2,804 shares of common stock were disposed of at a price of $19.36 per share to satisfy tax withholding obligations.
• After these transactions, Oelschlager directly beneficially owns 171,800 shares of Castle Biosciences common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the conversion of performance-based stock units and subsequent sale of shares for tax withholding. The vesting of PSUs is a positive indicator of performance or tenure, but the transaction itself is neutral in terms of immediate company outlook.

Positives

• The conversion of performance-based stock units indicates the achievement of vesting conditions, which can reflect positive company performance or the executive's continued tenure.
• The transaction increases the direct ownership of the Chief Operating Officer in the company's common equity, aligning her interests with shareholders.

Negatives

• A portion of the acquired shares (2,804 shares) was immediately sold to cover tax liabilities, which, while a common practice, reduces the net increase in the executive's direct shareholding.

Risks

• NA

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Such transactions are routine for executives receiving equity compensation.

Comparison to Industry Standards

• This filing reports a standard equity compensation event (PSU conversion and tax withholding) for a corporate officer.
• Such transactions are common across industries for executives receiving performance-based or time-based equity awards.
• No specific comparable companies, projects, or results are mentioned in this filing.

Stakeholder Impact

• Shareholders: The transaction is a routine insider equity event and does not directly impact the company's operational performance or financial health. It slightly increases the public float of shares if the shares were newly issued, but the net effect on outstanding shares is minimal due to tax withholding.
• Employees: No direct impact on employees beyond the reporting person.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this insider transaction report.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the conversion of performance-based stock units and subsequent sale of shares to cover tax obligations. It does not provide new information regarding the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Castle Biosciences, CSTL, SEC Form 4, Insider Trading, Stock Units, Equity Compensation, Chief Operating Officer, Kristen Oelschlager, Stock Conversion, Tax Withholding